{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '1.', 'INTRODUCTION', 'The global annual incidence of cervical cancer is approximately 527 000 cases per year, and there', 'are approximately 265 000 deaths (Torre 2015). The highest incidence rates are in the Caribbean,', 'Africa, Eastern Europe, and South America (Forman 2012). In the United States (US), there are', 'approximately 13000 new cases and 4100 deaths annually (Siegel 2016). In most cases, causation', 'is due to infection with human papillomavirus (HPV). Although vaccination against high risk', 'strains of HPV is projected to gradually decrease the global incidence of cervical cancer in the', 'next 15 years, the burden of this disease remains profound (Bray 2012).', 'For patients with locally advanced disease, curative intent therapy is definitive radiation with', 'concurrent cisplatin. However, recurrent or metastatic disease occurs in approximately one third', 'of cervical cancer patients in the US. For women with recurrent or metastatic disease, the GOG240', 'study established that standard first line therapy is platinum plus taxane doublet with the addition', 'of bevacizumab if clinically appropriate. Median survival with the triplet regimen is 17 months', '(Tewari 2014).', 'After progression on first line platinum-taxane based chemotherapy for recurrent or metastatic', 'disease, there is no standard of care. Non-randomized phase 2 trials have demonstrated survival', 'times of 7.4 to 8.1 months (N = 29 and 43 patients, respectively) with single agent pemetrexed', 'monotherapy (Lorusso 2010) (Miller 2008). Gemcitabine monotherapy yielded median overall', 'survival (OS) of 6.5 months in a phase 2 study of women (N = 22 patients) with previously treated', 'cervical cancer (Schilder 2005). In a phase 2 study (N = 45 patients) of topotecan in which most', 'patients had received prior platinum, median os was 6.6 months (Bookman 2000). In phase', '2 studies of vinorelbine for patients who could have received 1 prior chemotherapy regimen for', 'squamous or non-squamous advanced cervical cancer, observed response rates were 13%', '(6/44 patients) and 7% (2/28 patients), respectively (Muggia 2004) (Muggia 2005). Weekly', 'dosing of irinotecan yielded a response rate of 13% (6/45 patients) in a phase 2 study for women', 'with recurrent squamous cervical cancer in the US (Look 1998), and a response rate of 24%', '(13/55 patients) in a phase 2 study for women with cervical cancer in Japan (Takeuchi 1991). New', 'systemic therapy options are needed for this patient population.', 'Cemiplimab (the INN for REGN2810) is a hinge-stabilized IgG4P anti-PD-1 (programmed cell', 'death 1) monoclonal antibody that has demonstrated encouraging efficacy and favorable', 'tolerability in a phase 1 study that is now enrolling patients in multiple expansion cohorts', '(Papadopoulos 2016) (NCT02383212). Cemiplimab is also being evaluated in various clinical', 'trials and indications globally. On 28 September 2018, cemiplimab was approved in the US by', 'the Food and Drug Administration (FDA) as LIBTAYOR (cemiplimab-rwlc) for the treatment', 'of', 'patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC', 'who are not candidates for curative surgery or curative radiation.', 'The current study seeks to evaluate the clinical efficacy of cemiplimab in patients with recurrent', 'or metastatic cervical cancer that has progressed after platinum-based therapy. Programmed cell', 'death 1 is expressed on activated T-cells, and binding of PD-1 to its ligands, PD-L1 and PD-L2,', 'imparts inhibition of cytotoxic T-cell activity (Francisco 2010). Upregulated expression of', 'PD-1/PD-L1 checkpoint signaling in the tumor microenvironment plays a role in resistance to', 'antitumor immune responses (Zou 2008). The clinical study of cemiplimab in cervical cancer is', 'supported by both preclinical and clinical observations regarding the role of PD-1/PD-L1', 'Regeneron Pharmaceuticals, Inc.', 'Page 35 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'checkpoint signaling in the suppression of anti-tumor immune responses against this and other', 'HPV-associated cancers.', 'First, almost all cervical squamous cell carcinomas are associated with high risk strains of HPV', '(The Cancer Genome Atlas Research Network). Tumors that express viral antigen appear to be', 'responsive to PD-1 blockade as a strategy to enhance the antitumor immune response, as', 'demonstrated by positive clinical trial results in patients with HPV-associated head and neck', 'squamous cell carcinoma and in polyomavirus-associated Merkel Cell carcinoma, with nivolumab', 'and pembrolizumab, respectively (Gillison 2016) (Nghiem 2016). Secondly, cervical squamous', 'carcinomas may evade immune response by expression of PD-L1 ligand, which was detectable by', 'immunohistochemistry (>5% staining) in 54% (83/154) of squamous tumors, and in 14% (7/49)', 'of adenocarcinomas (Heeren 2016).', 'Thirdly, preliminary clinical data demonstrate efficacy of PD-1 blockade against cervical cancer.', 'In a cohort of 24 cervical cancer patients with PD-L1+ recurrent or metastatic cervical cancer', 'treated with pembrolizumab, objective responses were observed in 17% (4/24) of patients and', 'median os was 9 months (95% confidence interval [CI]: 4 to 12 months) (Frenel 2016). In the', 'first-in-human (FIH) study of cemiplimab, 3 patients with cervical squamous cancer were enrolled', 'in dose escalation cohorts to receive cemiplimab plus hypofractionated radiation therapy (9 gray', '[Gy] X 3 fractions or 6 Gy X 5 fractions) (Papadopoulos 2016). Two of these patients have', 'experienced durable responses. Radiation therapy was administered in week 2, and cemiplimab', 'was administered intravenously (IV) every 2 weeks (Q2W) for up to 48 weeks or until progression', 'of disease or unacceptable toxicity. Non-radiated lesions were evaluated for response. One patient', 'has experienced a radiologic complete response (CR), and another has experienced an overall', 'partial response (CR in target lesions, with a non-target lesion that persisted). Both patients', 'completed 48 weeks of treatment, and entered post-treatment follow up. The cervical cancer', 'patient with partial response experienced progressive disease (PD) with an enlarging', 'supraclavicular node after approximately 8 months of post-treatment follow up, and this was', 'biopsy-proven. This patient resumed treatment with cemiplimab monotherapy (no radiation) and', 'experienced a partial response at the first response assessment (8 weeks) after resuming treatment.', 'Fourth, analysis of gene expression data in The Cancer Genome Atlas (TCGA)', '(The Cancer Genome Atlas Research Network) demonstrates similarities between cervical cancer', 'and other tumor types for which anti-PD-1 therapy achieves therapeutic advantage. Briefly,', 'average expression of 3 genes (CD8A, PD-1, and PD-L1) in each tumor type is normalized to', 'standard distribution across all tumor types. Tumors are organized according to Z-scores using', 'hierarchical clustering (Figure 1). Cervical cancer clusters with non-small cell lung cancer,', 'melanoma, renal clear cell carcinoma, and head and neck squamous cell carcinoma. Programmed', 'cell death 1 blockade improved OS in each of these tumor types in randomized phase 3 studies', '(Ferris 2016) (Motzer 2015) (Trivedi 2015).', 'Taken together, these observations suggest that a prospective randomized trial of PD-1 inhibition', 'with cemiplimab is warranted for patients with recurrent/metastatic cervical cancer to potentially', 'improve OS.', 'Regeneron Pharmaceuticals, Inc.', 'Page 36 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}